Lysosomal storage diseases: Natural history and ethical and economic aspects

Molecular Genetics and Metabolism

Volumn 88, Issue 3, 2006, Pages 208-215

  Beutler, Ernest ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Cost; Enzyme replacement; Fabry disease; Gaucher disease; Health care; Substrate reduction

Indexed keywords

CHAPERONE; ENZYME;

BUDGET; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DRUG COST; DRUG MARKETING; ECONOMIC ASPECT; ENZYME REPLACEMENT; ENZYME SUBSTRATE; ETHICS; GAUCHER DISEASE; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE PLANNING; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; LYSOSOME STORAGE DISEASE; MAINTENANCE THERAPY; MUTATION; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SOCIETY;

ETHICS, CLINICAL; GAUCHER DISEASE; GLUCOSYLCERAMIDASE; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; LYSOSOMAL STORAGE DISEASES; PATIENT SELECTION;

EID: 33745506072     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2006.01.010     Document Type: Review

References (43)

1. National School Lunch Program (NSLP). 2005.
2. Achord D.T., Brot F.E., Bell C.E., and Sly W.S. Human beta-glucuronidase: in vivo clearance and in vitro uptake by a glycoprotein recognition system on reticuloendothelial cells. Cell 15 (1978) 269-278
3. Altarescu G., Schiffmann R., Parker C.C., Moore D.F., Kreps R.N., Brady R.O., and Barton N.W. Comparative efficacy of dose regimens in enzyme replacement therapy of type 1 Gaucher disease. Blood Cells Mol. Dis. 26 (2000) 285-290
4. G.Anand, How drugs for rare diseases became lifeline for companies, The Wall Street Journal 2005, Dow-Jones, 11-15-0005.
5. G.Anand, Why genzyme can charge so much for Cerezyme, The Wall Street Journal 2005, Dow-Jones, 11-17-2005.
6. Baldellou A., Andria G., Campbell P.E., Charrow J., Cohen I.J., Grabowski G.A., Harris C.M., Kaplan P., McHugh K., Mengel E., and Vellodi A. Paediatric non-neuronopathic Gaucher disease: recommendations for treatment and monitoring. Eur. J. Pediatr. 163 (2004) 67-75
7. Balicki D., and Beutler E. Gaucher disease. Medicine 74 (1995) 305-323
8. Barton N.W., Brady R.O., and Dambrosia J.M. Treatment of Gaucher's disease. N. Engl. J. Med. 328 (1993) 1564-1565
9. Barton N.W., Brady R.O., Dambrosia J.M., Di Bisceglie A.M., Doppelt S.H., Hill S.C., Mankin H.J., Murray G.J., Parker R.I., Argoff C.E., Grewal R.P., and Yu K.-T. Replacement therapy for inherited enzyme deficiency - Macrophage-targeted glucocerebrosidase for Gaucher's disease. N. Engl. J. Med. 324 (1991) 1464-1470
10. Barton N.W., Furbish F.S., Murray G.J., Garfield M., and Brady R.O. Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with Gaucher disease. Proc. Natl. Acad. Sci. USA 87 (1990) 1913-1916
11. Belchetz P.E., Crawley J.C.W., Braidman I.P., and Gregoriadis G. Treatment of Gaucher's disease with liposome-entrapped glucocerebroside: Beta-glucosidase. Lancet 2 (1977) 116-117
12. Beutler E. Gaucher disease as a paradigm of current issues regarding single gene mutations of humans. Proc. Natl. Acad. Sci. USA 90 (1993) 5384-5390
13. Beutler E. Treatment regimens in Gaucher's disease. Lancet 346 (1995) 581-582
14. Beutler E. Enzyme replacement therapy for Gaucher disease. Baillieres Clin. Haematol. 10 (1997) 711-723
15. Beutler E. Commentary: dosage-response in the treatment of Gaucher disease by enzyme replacement therapy. Blood Cells Mol. Dis. 26 (2000) 303-306
16. Beutler E., and Dale G.L. Enzyme replacement therapy. In: Atkinson D., and Fox C.F. (Eds). Covalent and Non-covalent Modulation of Protein Function (1979), Academic Press, New York 449-461
17. Beutler E., Dale G.L., Guinto E., and Kuhl W. Enzyme replacement therapy in Gaucher's disease: preliminary clinical trial of a new enzyme preparation. Proc. Natl. Acad. Sci. USA 74 (1977) 4620-4623
18. Beutler E., Dale G.L., and Kuhl W. Enzyme replacement with red cells. N. Engl. J. Med. 296 (1977) 942-943
19. Beutler E., Dale G.L., and Kuhl W. Replacement therapy in Gaucher's disease. In: Desnick R.J. (Ed). Enzyme Therapy in Genetic Diseases: 2 (1980), Alan R. Liss, New York 369-381
20. Beutler E., Demina A., Laubscher K., Garver P., Gelbart T., Balicki D., and Vaughan L. The clinical course of treated and untreated Gaucher disease. A study of 45 patients. Blood Cells Mol. Dis. 21 (1995) 86-108
21. Brady R.O., Barranger J.A., Furbish F.S., Stowens D.W., and Ginns E.I. Prospects for enzyme replacement therapy in Gaucher Disease. In: Desnick R.J., Gatt S., and Grabowski G.A. (Eds). Gaucher Disease: A Century of Delineation and Research (1982), Alan R. Liss, New York 669-680
22. Brady R.O., Pentchev P.G., Gal A.E., Hibbert S.R., and Dekaban A.S. Replacement therapy for inherited enzyme deficiency. Use of purified glucocerebrosidase in Gaucher's disease. N. Engl. J. Med. 291 (1974) 989-993
23. Dale G.L., and Beutler E. Enzyme therapy in Gaucher disease: clinical trials and model system studies. In: Crawford M.A., Gibbs D.A., and Watts R.W.E. (Eds). Advances in the Treatment of Inborn Errors of Metabolism (1982), John Wiley and Sons, New York 77-91
24. DeDuve C. From cytases to lysosomes. Fed. Proc. 23 (1964) 1045-1049
25. Elstein D., Abrahamov A., Hadas-Halpern I., and Zimran A. Withdrawal of enzyme replacement therapy in Gaucher's disease. Br. J. Haematol. 110 (2000) 488-492
26. Fallet S., Sibille A., Mendelson R., Shapiro D., Hermann G., and Grabowski G.A. Enzyme augmentation in moderate to life- threatening Gaucher disease. Pediatr. Res. 31 (1992) 496-502
27. Figueroa M.L., Rosenbloom B.E., Kay A.C., Garver P., Thurston D.W., Koziol J.A., Gelbart T., and Beutler E. A less costly regimen of alglucerase to treat Gaucher's disease. N. Engl. J. Med. 327 (1992) 1632-1636
28. Giraldo P., Pocovi M., Perez-Calvo J.I., Pubio-Felix D., and Giralt M. Report of the Spanish Gaucher's Disease Registry: clinical and genetic characteristics. Haematologica 85 (2000) 792-799
29. Grabowski G.A., Barton N.W., Pastores G., Dambrosia J.M., Banerjee T.K., McKee M.A., Parker C., Schiffmann R., Hill S.C., and Brady R.O. Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. Ann. Intern. Med. 122 (1995) 33-39
30. Gregoriadis G., Neerunjun D., Meade T.W., Goolamali S.K., Weereratne H., and Bull G. Experiences after long-term treatment of a type I Gaucher disease patient with liposome-entrapped glucocerebroside: Beta-glucosidase. In: Desnick R.J. (Ed). Enzyme Therapy in Genetic Diseases: 2 (1980), Alan R. Liss, New York 383-392
31. Grinzaid K.A., Geller E., Hanna S.L., and Elsas L.J. Cessation of enzyme replacement therapy in Gaucher disease. Genet. Med. 4 (2002) 427-433
32. Hollak C.E.M., Aerts J.M.F.G., Goudsmit R., Phoa S.S.K.S., Ek M., van Weely S., von dem Borne A.E.G.Kr., and van Oers M.H.J. Individualised low-dose alglucerase therapy for type 1 Gaucher's disease. Lancet 345 (1995) 1474-1478
33. Ida H., Rennert O.M., Ito T., Maekawa K., and Eto Y. Type 1 Gaucher disease: phenotypic expression and natural history in Japanese patients. Blood Cells Mol. Dis. 24 (1998) 73-81
34. International Collaborative Gaucher Group Registry, Genzyme Therapeutics, Dosage regimens of alglucerase in Gaucher disease: a comparison of the rate and extent of clinical response, ICGG Registry Update (1995) 1-11.
35. Jacobson S.H., Sewell E.C., and Karnani T. Engineering the economic value of two pediatric combination vaccines. Health Care Manag. Sci. 8 (2005) 29-40
36. Maaswinkel-Mooij P., Hollak C., Eysden-Plaisier M., Prins M., Aerts H., and Poll R. The natural course of Gaucher disease in The Netherlands: implications for monitoring of disease manifestations. J. Inherit. Metab. Dis. 23 (2000) 77-82
37. Pastores G.M., Sibille A.R., and Grabowski G.A. Enzyme therapy in Gaucher disease type 1: dosage efficacy and adverse effects in thirty-three patients treated for 6 to 24 months. Blood 82 (1993) 408-416
38. Povar G.J., Blumen H., Daniel J., Daub S., Evans L., Holm R.P., Levkovich N., McCarter A.O., Sabin J., Snyder L., Sulmasy D., Vaughan P., Wellikson L.D., and Campbell A. Ethics in Practice: managed care and the changing health care environment: medicine as a profession managed care ethics working group statement. Ann. Intern. Med. 141 (2004) 131-136
39. Schein P.S. The case for a new national program for the development of cancer therapeutics. J. Clin. Oncol. 19 (2001) 3142-3153
40. A.Zimran, Personal communication, 2006.
41. Zimran A., Elstein D., Kannai R., Zevin S., Hadas-Halpern I., Levy-Lahad E., Cohen Y., Horowitz M., and Abrahamov A. Low-dose enzyme replacement therapy for Gaucher's disease: effects of age, sex, genotype, and clinical features on response to treatment. Am. J. Med. 97 (1994) 3-13
42. Zimran A., Elstein D., Levy-Lahad E., Zevin S., Hadas-Halpern I., Bar-Ziv Y., Foldes J., Schwartz A.J., and Abrahamov A. Replacement therapy with imiglucerase for type 1 Gaucher's disease. Lancet 345 (1995) 1479-1480
43. Zimran A., Kay A.C., Gelbart T., Garver P., Saven A., and Beutler E. Gaucher disease: clinical, laboratory, radiologic and genetic features of 53 patients. Medicine 71 (1992) 337-353